The spinout, dubbed Antares Therapeutics, will be fueled by a $177 million series A round co-led by Omega Funds, Atlas ...

Additional support came from Abingworth, Invus, Tenmile, Vida Ventures, Vinyanshu Ventures and Willett Advisors.

Antares Therapeutics, Inc. ("Antares"), a biotechnology company developing first-in-class precision medicines for cancer and ...

Five months after selling a cancer drug to Lilly for up to $2.5 billion, Scorpion has debuted a successor company led by its ...

Boston, USA-based biotech Antares Therapeutics, launched yesterday with $177 million in Series A financing. Antares is a spin ...

The Scorpion Therapeutics spinoff sold rights for two EGFR inhibitors to Pierre Fabre Laboratories and is hoping to become a clinical-stage firm by 2026.

The rest of Scorpion’s assets were to be spun out into a new company. That startup, Boston-based Antares Therapeutics, launched Tuesday. Scorpion was founded in 2020 by serial biotech ...

Antares Therapeutics spun off of Scorpion Therapeutics, a clinical-stage biotech that Eli Lilly acquired earlier this year. Like Scorpion, Antares is developing small molecules that go after ...